Chinese biopharma specializing in recombinant protein drugs, notably long-acting pegylated interferon.
Chinese biopharma specializing in recombinant protein drugs, notably long-acting pegylated interferon.
Sells its long-acting interferon mainly to hospitals through distributors, so sales rest on one product family, and hospital tenders and inclusion on China's insurance reimbursement lists set price and volume. Competing imported and domestic long-acting interferons keep price pressure on it.
In one line: A small, interferon-focused Chinese biologics maker.
Moat: narrow (IP / patents, regulatory licence). One of few domestic makers of long-acting pegylated interferon, reducing reliance on imports.
Headquarters: Xiamen, China · Employees: 3,644
Size Xiamen Amoytop Biotech (688278.SS) is a China Health Care company (Biotechnology) with a market value of $2.56B, the 928th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥42.14 on 18 Nov 2026.
Performance Over six months the shares fell 27.1%, against -2.0% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 18.3% over the last twelve months (peer median +9.4%); the operating margin is 26.7% (peer median -22.7%).
Valuation It trades at 15.0× forward earnings against a peer median of 36.4× (cheapest of 7).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +36%, so the hurdle is -37 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 22.7 points above its cost of capital (5.3% WACC).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.95B | CN¥3.68B | CN¥2.81B | CN¥2.09B | CN¥1.52B |
| Revenue growth | — | +31% | +34% | +38% | — |
| Gross profit | CN¥3.64B | CN¥3.37B | CN¥2.61B | CN¥1.94B | CN¥1.34B |
| EBITDA | n/a | CN¥1.36B | CN¥1.02B | CN¥728M | CN¥410M |
| Net income | CN¥842M | CN¥1.03B | CN¥828M | CN¥555M | CN¥287M |
| Free cash flow | CN¥260M | CN¥473M | CN¥179M | CN¥224M | CN¥144M |
| Capital expenditure | CN¥307M | CN¥256M | CN¥251M | CN¥288M | CN¥219M |
| Total debt | CN¥2.20B | CN¥176M | CN¥8.94M | CN¥7.92M | CN¥9.74M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Xiamen Amoytop Biotech 688278.SS | $2.56B | -27% | +18% | 27% | 15.0× | -0.6% |
| Sinocelltech 688520.SS | $1.90B | -35% | -40% | -75% | n/a | n/a |
| Roche RO.SW | $381B | +21% | -1% | 31% | 19.9× | 1.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688278.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.5% | -2.6% | 8th lowest of 21 |
| 6-month return | -27.1% | -2.0% | 5th lowest of 21 |
| Distance from 52-week high | -50.8% | -30.1% | 4th lowest of 21 |
| Revenue growth (TTM) | +18.3% | +9.4% | 8th highest of 17 |
| Operating margin | 26.7% | -22.7% | 3rd highest of 18 |
| Forward P/E | 15.0× | 36.4× | cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | -0.6% | 6.3% | 3rd least demanding of 5 |
| Growth delivered (Del g) | +36.0% | +35.9% | 3rd highest of 5 |
| Hurdle (Req g minus delivered) | -36.6 pp | -31.4 pp | 2nd least demanding of 5 |
| ROIC minus cost of capital | +22.7 pp | -9.4 pp | 3rd highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Xiamen Amoytop Biotech 688278.SS | China | $2.56B | -27% | +18% | 27% | 15.0× | -0.6% | +36.0% |
| Xencor XNCR | United States | $2.58B | +204% | +34% | -73% | n/a | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.48B | -26% | -23% | 5% | 348.7× | 29.5% | -3.8% |
| MBX Biosciences MBX | United States | $2.65B | +70% | n/a | n/a | n/a | n/a | n/a |
| HLB 028300.KS | South Korea | $2.69B | -49% | +26% | -96% | n/a | n/a | n/a |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.72B | -7% | +20% | -3% | n/a | n/a | n/a |
| Zai Lab 9688.HK | Hong Kong | $2.79B | +23% | 0% | -63% | n/a | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.33B | -59% | 0% | -25% | n/a | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.82B | +23% | -8% | 18% | 16.6× | -4.3% | +27.4% |
| XtalPi 2228.HK | Hong Kong | $2.87B | -34% | +4% | -127% | n/a | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.27B | -34% | -58% | -475% | n/a | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.26B | +31% | +223% | 64% | n/a | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +51% | +8% | 19% | 38.4× | 13.4% | +44.5% |
| SKBS 302440.KS | South Korea | $2.25B | -12% | +11% | -23% | n/a | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.94B | +68% | +37% | 21% | 66.6× | n/a | n/a |
| Denali Therapeutics DNLI | United States | $2.95B | -2% | n/a | -2,488% | n/a | n/a | n/a |
| Pharvaris PHVS | United States | $2.21B | +7% | n/a | n/a | n/a | n/a | n/a |
| Dyne Therapeutics DYN | United States | $2.97B | -10% | n/a | n/a | n/a | n/a | n/a |
| Telix Pharmaceuticals TLX.AX | Australia | $2.99B | -2% | +27% | -1% | 34.5× | n/a | n/a |
| ADMA Biologics ADMA | United States | $3.01B | +58% | +6% | 45% | 16.7× | -0.8% | +64.6% |
| Beam Therapeutics BEAM | United States | $2.17B | -22% | +163% | -268% | n/a | n/a | n/a |